Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 737488
Species: Mus musculus
RGD Object: Gene
Symbol: Ifng
Name: interferon gamma
Acc ID: CHEBI:9763
Term: trovafloxacin
Definition: A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.
Chemical ID: MESH:C080163
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Ifngmultiple interactionsEXP 6480464CTDIFNG protein promotes the reaction [[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF protein]; IFNG protein results in increased susceptibility to [trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5]; trovafloxacin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNG protein]; trovafloxacin promotes the reaction [TNF protein results in increased expression of IFNG protein]PMID:18930950 PMID:19638433
Ifngmultiple interactionsISOIfng (Rattus norvegicus)6480464CTD[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacinPMID:19362101
Ifngmultiple interactionsISOIFNG (Homo sapiens)6480464CTD[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to trovafloxacinPMID:19362101
Go Back to source page   Continue to Ontology report